Today, Emergent BioSolutions Inc. (NYSE: EBS) announced
NARCAN® Naloxone HCl Nasal Spray 4 mg will be available on
shelves nationwide and online beginning in September.
Over-the-counter (OTC) access to NARCAN® Nasal Spray offers more
people the ability to respond in an opioid emergency, helping to
save lives and keep loved ones and communities safe. Expanding
access and awareness is critical given the staggering toll of the
epidemic mainly driven by synthetic opioids, like fentanyl.1 Last
year, approximately every seven minutes one life was lost due to an
opioid overdose, and today it is the leading cause of accidental
death in the U.S.2,3 The average response time for emergency
services to arrive is approximately 10 minutes.4 Having
NARCAN
® Nasal Spray in a first-aid kit, or
carrying it on the go in case of an opioid emergency, can make a
difference and help reverse the effects of opioids while waiting
for emergency personnel to arrive.
“As a medical professional and mom who experienced the
unthinkable and lost both of her sons to accidental overdose, I
know you can’t put a price on peace of mind and there is no act too
great to protect family,” said Dr. Bonnie Milas, Penn Medicine
physician and professor of Clinical Anesthesiology and Critical
Care. “Picking up NARCAN® Nasal Spray at the store is not a sign
that your family has “a problem,” in fact it shows you are prepared
just in case. It’s like buying a fire extinguisher to have at home
– having the power to save a life of someone you love, someone you
know, or someone that may need another chance.”
With the same safe and effective 4 mg formulation, device design
and original prescription strength, NARCAN® Nasal Spray can reverse
the effects of opioids, including fentanyl. Consumers can expect
the life-saving treatment to be widely available at leading mass,
drug, grocery and online retailers beginning in September. The
Manufacturer’s Suggested Retail Price of NARCAN® Nasal Spray is
$44.99 per carton, which is equivalent to roughly $22.50 per dose.
While Emergent works with partners to help maintain access and
affordability, the price of the product is set by individual
retailers.
“A steadfast commitment to expanding access to naloxone has
always been at the forefront of our work to help save lives and
we’re proud to bring NARCAN® Nasal Spray to many, many more
places,” said Paul Williams, senior vice president, products
business. “Expanding availability to online and in-store shelves,
increasing awareness and education to reduce stigma, and calling on
the public to be prepared, is additive to the current work Emergent
does every single day to stem the tide of this public health
threat. On the eve of International Overdose Awareness Day, we
stand by our ongoing efforts with advocates, patients, customers
and policy stakeholders to implement efforts that enhance naloxone
distribution to all those in need.”
As a leader in the fight against the opioid crisis, Emergent has
not raised the price of the product since its launch in 2016, and
the company is focused on broadening distribution and maintaining
affordability. To that end, Emergent has lowered its public
interest price for NARCAN® Nasal Spray to $41.00 per two-dose
carton, effective August 31, 2023, building on its long-standing
efforts with public interest partners to ensure naloxone is readily
available to at-risk communities. Through federal grants and state
and local government programs, many community organizations, first
responders, and harm reduction groups can purchase NARCAN® Nasal
Spray and distribute it at no cost to them. These programs help
ensure life-saving products are available in communities across the
country, particularly those that may be unable to reach life-saving
medical care quickly in emergencies. While the public interest
distribution channels are vast, many qualified groups can continue
to use Emergent’s online portal, NARCANDirect™, as one pathway to
purchase and ship bulk quantities of NARCAN® Nasal Spray to
anywhere in the country.
According to a March 2023 report by the Reagan-Udall Foundation,
almost 17 million doses of naloxone were distributed in the U.S. in
2021. More than 84 percent of those doses were distributed through
channels such as local health departments, harm reduction
organizations, first responders, schools, and other community
organizations.5 Emergent recognizes the importance of these
channels for naloxone access and will continue to support ongoing
distribution to high-risk and underserved communities in need.
With the prescription approval of NARCAN® Nasal Spray in 2015,
Emergent has more than seven years of real-world safety data, and
continues to evaluate trends across society, new opioid threats
and is committed to doing its part in fighting the opioid
epidemic.
For more information, visit NARCAN.com.
About NARCAN® Nasal Spray
NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved,
over-the-counter (OTC) 4 mg naloxone product for the emergency
treatment of opioid overdose. NARCAN® Nasal Spray is not a
substitute for emergency medical care. Repeat dosing may be
necessary. Use as directed.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25
years, we’ve been at work defending people from things we hope will
never happen—so we are prepared just in case they ever do. We
provide solutions for complex and urgent public health threats
through a portfolio of vaccines and therapeutics that we develop
and manufacture for governments and consumers. We also offer a
range of integrated contract development and manufacturing services
for pharmaceutical and biotechnology customers. To learn more about
how we plan to protect or enhance 1 billion lives by 2030, visit
our website and follow us on LinkedIn, Twitter,
and Instagram.
Safe Harbor Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical fact,
including statements regarding the development and commercial
availability of NARCAN® Naloxone HCl Nasal Spray 4 mg
over-the-counter are forward-looking statements. We generally
identify forward-looking statements by using words like
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,”
“would,” and similar expressions or variations thereof, or the
negative thereof, but these terms are not the exclusive means of
identifying such statements. Forward-looking statements are based
on our current intentions, beliefs and expectations regarding
future events. We cannot guarantee that any forward-looking
statement will be accurate. Readers should realize that if
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could differ materially
from our expectations. Readers are, therefore, cautioned not to
place undue reliance on any forward-looking statement. Any
forward-looking statement speaks only as of the date of this press
release, and, except as required by law, we do not undertake to
update any forward-looking statement to reflect new information,
events or circumstances. There are a number of important factors
that could cause the company’s actual results to differ materially
from those indicated by any forward-looking statements. Readers
should consider this cautionary statement, as well as the risk
factors identified in our periodic reports filed with the U.S.
Securities and Exchange Commission, when evaluating our
forward-looking statements.
Emergent BioSolutions Contacts:
Media:Matt HartwigSenior Director, Media
Relations240-760-0551mediarelations@ebsi.com
Investors:Richard LindahlEVP and Chief Financial
Officer240-631-3360lindahlr@ebsi.com
1 Centers for Disease Control and Prevention. Understanding the
epidemic. Available at:
https://www.cdc.gov/opioids/basics/epidemic.html. Updated June 1,
2022. Accessed August 25, 2023.2 Centers for Disease Control and
Prevention. Provisional Drug Overdose Death Counts. Available at:
https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Updated
February 15, 2023. Accessed August 25, 2023.3 Schiller EY, Goyal A,
Mechanic OJ. Opioid overdose. NCBI Bookshelf. A service of the
National Library of Medicine, National Institutes of Health.
Available at: https://www.ncbi.nlm.nih.gov/books/NBK470415/.
Updated April 29, 2023. Accessed August 25, 2023.4 Gonzalez RP,
Cummings GR, Mulekar MS, et al. Improving rural emergency medical
service response time with global positioning system navigation. J.
Trauma. 2009 Nov;67(5):899-902.5 Reagan-Udall Foundation. Naloxone
economic view: Summary report. March 2023. Available at:
https://reaganudall.org/sites/default/files/2023-03/Naloxone%20Report%20FINAL%203.10.23.pdf.
Accessed August 25, 2023.
Photos accompanying this announcement are available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/5821a1af-a5b2-4a31-8e5d-1d35ee600799https://www.globenewswire.com/NewsRoom/AttachmentNg/5536cab5-295f-45de-91c9-1bfa1db49150
Emergent Biosolutions (NYSE:EBS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Emergent Biosolutions (NYSE:EBS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024